<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785534</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0978</org_study_id>
    <secondary_id>NCI-2021-00214</secondary_id>
    <nct_id>NCT04785534</nct_id>
  </id_info>
  <brief_title>Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis</brief_title>
  <official_title>Patient-Centered Liver Cancer Prevention in the Houston Community Screening for Predictors of Fibrosis and Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the use of surveys, blood testing, and fibroscan in screening for&#xD;
      liver fibrosis and liver cirrhosis in new or existing patients of the HOPE clinic seeking&#xD;
      usual clinical care. Fibroscan is an imaging procedure of the liver which uses a probe like&#xD;
      an ultrasound. Information gathered from this study may help researchers learn more about how&#xD;
      to prevent or find liver cancer in patients who are currently receiving care at the HOPE&#xD;
      clinic. Early detection of liver cancer may improve survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the sensitivity of the modified Center for Disease Control (CDC) hepatitis&#xD;
      survey in diagnosing chronic hepatitis B virus (HBV) among HOPE clinic patient.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the sensitivity of the modified CDC hepatitis survey in identifying chronic&#xD;
      active hepatitis C virus (HCV) infection among HOPE clinic patients.&#xD;
&#xD;
      II. To estimate the sensitivity of fibrosis serum biomarkers, non-alcoholic fatty liver&#xD;
      disease fibrosis score (NFS), fibrosis-4 index (FIB-4), and fatty liver index (FLI) in&#xD;
      detecting fibrosis (fibroscan result &gt;= F2) among HOPE clinic patients with metabolic&#xD;
      conditions.&#xD;
&#xD;
      III. To estimate the sensitivity of the Alcohol Use Disorder Identification Test Alcohol&#xD;
      Consumption (AUDIT-C) in identifying fibrosis (fibroscan result &gt;= F2) among HOPE clinic&#xD;
      patients.&#xD;
&#xD;
      IV. To estimate the sensitivity of the AUDIT-10 survey in identifying fibrosis (Fibroscan&#xD;
      result &gt;= F2) among Hope Clinic patients who scored &gt;= 4 for men or &gt;= 3 for women on the&#xD;
      AUDIT-C.&#xD;
&#xD;
      V. To estimate the specificity and accuracy of each of these risk factor screening tools in&#xD;
      HOPE clinic patients.&#xD;
&#xD;
      VI. To estimate the prevalence of fibrosis and cirrhosis risk factors among HOPE clinic&#xD;
      patients.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To explore factors associated with each fibrosis/cirrhosis risk factor. II. To investigate&#xD;
      differential diagnostic accuracy of screening methods by fibrosis severity.&#xD;
&#xD;
      III. To evaluate the diagnostic performance of each dichotomized biomarker (NFS, FIB-4, and&#xD;
      FLI) separately and assess biomarker optimal cutpoints for identifying fibrosis in the study&#xD;
      population.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation,&#xD;
      and fibroscan at baseline.&#xD;
&#xD;
      After completion of study, patients are followed up at 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive hepatitis B surface antigen test result</measure>
    <time_frame>At baseline</time_frame>
    <description>The presence of at least one risk factor for hepatitis B virus (HBV) on the screening questionnaire will indicate a positive (versus negative) screening for HBV infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive anti-hepatitis C virus (HCV) test result</measure>
    <time_frame>At baseline</time_frame>
    <description>Will assess positive anti-HCV test result AND either 1) detectable HCV ribonucleic acid, or 2) history of HCV infection and past anti-HCV treatment. Will estimate the prevalence and exact binomial 95% confidence intervals for each of the fibrosis and cirrhosis risk factors examined in this study. For each risk factor, we will first present a cross tabulation of the dichotomous screening test result by the dichotomous gold standard result. To evaluate the performance of each screening method, will calculate point estimates and 95% confidence intervals for the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan result &gt;= F2</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Will estimate the prevalence and exact binomial 95% confidence intervals for each of the fibrosis and cirrhosis risk factors examined in this study. For each risk factor, we will first present a cross tabulation of the dichotomous screening test result by the dichotomous gold standard result. To evaluate the performance of each screening method, will calculate point estimates and 95% confidence intervals for the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Liver and Intrahepatic Bile Duct Carcinoma</condition>
  <arm_group>
    <arm_group_label>Screening (survey, biomarker analysis, fibroscan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Evaluation</intervention_name>
    <description>Undergo clinical evaluation</description>
    <arm_group_label>Screening (survey, biomarker analysis, fibroscan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Screening (survey, biomarker analysis, fibroscan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Ultrasonographic Elastography</intervention_name>
    <description>Undergo fibroscan</description>
    <arm_group_label>Screening (survey, biomarker analysis, fibroscan)</arm_group_label>
    <other_name>Fibroscan</other_name>
    <other_name>TE</other_name>
    <other_name>Transient Elastography</other_name>
    <other_name>VCTE</other_name>
    <other_name>Vibration-Controlled Transient Elastrography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Complete survey</description>
    <arm_group_label>Screening (survey, biomarker analysis, fibroscan)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be at least 18 years old&#xD;
&#xD;
          -  Must be a new or existing patient of the HOPE clinic seeking usual clinical care&#xD;
&#xD;
          -  Must be able to speak and read English or a language other than English for which&#xD;
             there is a translator available on site at the HOPE clinic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy at time of recruitment. The HOPE clinic will ask the female patients&#xD;
             if they are pregnant, will ask the participants for their last menstrual period (LMP),&#xD;
             and/or they will use the urine pregnancy test (UPT) results in their electronic&#xD;
             medical records&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica P Hwang</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica P. Hwang</last_name>
      <phone>713-745-4516</phone>
      <email>jphwang@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jessica P. Hwang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

